Home > Maligne hematologie > Myeloïde ziekten > Acute myeloïde leukemie > AML (incl. APL) > MGD006-01

MGD006-01

A Phase 1/2, First-in-Human, Dose Escalation Study of MGD006, a CD123 x CD3 Dual Affinity Re-Targeting (DART) Bi-Specific Antibody-Based Molecule, in Patients with Relapsed or Refractory Acute Myeloid Leukemia or Intermediate-2/High Risk Myelodysplastic Syndrome

Deze print is 24 uur geldig na het aanmaken. Aangemaakt op: 29-5-2024, 20:10